Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
Date:1/24/2011

NOVATO, Calif., Jan. 24, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at 5:00 p.m. ET to discuss fourth quarter and full year 2010 financial results.U.S. / Canada Dial-in Number:  866.203.3206International Dial-in Number:  617.213.8848Participant Code: 90635895Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 22192303Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 1/2 clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 1/2 clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
2. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
3. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
4. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
5. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
6. BioMarin Announces Third Quarter 2010 Financial Results
7. BioMarin to Host a Research and Development Day on October 19th
8. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
9. BioMarin to Present at the UBS Global Life Sciences Conference
10. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
11. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
Breaking Medicine Technology:
(Date:5/2/2016)... Greifensee, Switzerland (PRWEB) , ... May 02, 2016 , ... ... Visual and performance artist Curt Walter has developed it into a science. , ... has helped Walter achieve subtly differentiated shades that add depth and meaning to his ...
(Date:5/2/2016)... ... May 02, 2016 , ... Summit BHC (Summit), a leading ... Twin Lakes Recovery Center. Located east of Atlanta in Monroe, Georgia, the ... residential facility is set on 34 acres of beautiful, secluded property that will ...
(Date:5/1/2016)... Francisco, California (PRWEB) , ... May 02, 2016 ... ... announces his search for original 1968 Jimi Hendrix Merriweather Post Pavilion in Columbia, ... Post Pavilion Hendrix concert poster. The concert was held on August 16. According ...
(Date:5/1/2016)... ... May 01, 2016 , ... Outdoor Growing Bans Are Sweeping California, which states ... the law in the hands of the local communities to decide each county’s ... allow counties to vote on growing regulations by 3/1/2016 or be forced to follow ...
(Date:4/30/2016)... ... April 30, 2016 , ... Powerful tools ... Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy and why after centuries, ... control), pain relief (chronic and acute), birthing processes and medical procedures, depression, anxiety, ...
Breaking Medicine News(10 mins):